Design Therapeutics, Inc.
HealthcareNASDAQ:DSGN · NASDAQ Global Select
+$0.44 today
Vol 0.46M · Avg 0.73M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.8%
avg 3.3%
ROIC
-37.3%
avg -11.5%
ROA
-30.9%
avg -342.6%
Analysis
ROA is currently the strongest return metric at -30.9% versus its period average of -342.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Pratik Shah | Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson | $790,000.00 | — | 56 | $750,000.00 | 1.20% |
Sean Jeffries | Chief Operating Officer | $698,000.00 | — | 46 | $375,000.00 | 0.60% |
Chris Storgard | Chief Medical Officer | $633,760.00 | — | 60 | $250,000.00 | 0.40% |
Aseem Z. Ansari | Co-Founder & Scientific Advisor | — | — | — | $100,000.00 | 0.16% |
Julie D. Burgess | Chief Accounting Officer | — | — | — | $30,000.00 | 0.05% |
Doane Chilcoat | Chief Technology Officer | — | — | — | — | — |
Jim Kerr | Chief of Manufacturing & Product Development | — | — | — | — | — |
Tadimeti S. Rao | Chief Scientific Officer | — | — | — | — | — |
Mustapha Parekh | General Counsel | — | — | — | — | — |
Chengzhi Zhang | Chief Chemist | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$2.95M
Net Sentiment
$2.95M
Net selling
Most Active
William Arsani
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Aug 13, 2025 | William Arsani Indirect | Sell | 345.0K | $5.25 | $1,811,250.00 | |
| Aug 13, 2025 | William Arsani Indirect | Sell | 217.6K | $5.25 | $1,142,541.75 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $2.95M over the last 12 months. That adds up to net selling of $2.95M. William Arsani was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$300.28M
I-Mab
IMAB
$235.66M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages DSGN?
Design Therapeutics, Inc. (DSGN) lists 10 active executives. The top listed executive is Aseem Z. Ansari, Co-Founder & Scientific Advisor.
Are DSGN insiders buying or selling?
Recent insider activity shows net buying of $128.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.